Understanding the Cross-Talk between Ovarian Tumors and Immune Cells: Mechanisms for Effective Immunotherapies

REFERENCES

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893–1907.
   PubMed Web of Science ®Google Scholar
• Cheng W, Liu J, Yoshida H, Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005;11:531–537.
   PubMed Web of Science ®Google Scholar
• Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol Oncol 2011;120:152–157.
   PubMedGoogle Scholar
• Russo A, Calo V, Bruno L, Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009;69:28–44.
   Google Scholar
• Coukos G, Rubin SC. Prophylactic oophorectomy. Best Pract Res Clin Obstet Gynaecol 2002;16:597–609.
   Google Scholar
• Salani R, Backes FJ, Copeland LJ. Overview of epithelial ovarian cancer and updates in management strategies. Expert Rev Obstet & Gynecol 2009;4:383–399.
   Google Scholar
• Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009;9:1727–1735.
   PubMed Web of Science ®Google Scholar
• Zhou G, Drake CT, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006;107:628–636.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St John E, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883–887.
   PubMed Web of Science ®Google Scholar
• Buller RE, Berman ML, Bloss JD, Serum CA125 regression in epithelial ovarian cancer: Correlation with reassessment findings and survival. Gynecol Oncol 1992;47:87–92.
   Google Scholar
• Cooper BC, Sood AK, Davis CS, Preoperative CA 125 levels: An independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002;100:59–64.
   PubMed Web of Science ®Google Scholar
• Alagoz T, Buller RE, Berman M, What is a normal CA125 level? Gynecol Oncol 1994;53:93–97.
   PubMed Web of Science ®Google Scholar
• Vermeij R, Daemen T, de Bock GH, Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010;891505:15.
   Google Scholar
• Drapkin R, von Horsten HH, Lin Y, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162–2169.
   PubMed Web of Science ®Google Scholar
• Huhtinen K, Suvitie P, Hiissa J, Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315–1319.
   PubMed Web of Science ®Google Scholar
• Schorge JO, Modesitt SC, Coleman RL, SGO White Paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol 2010; 119:7–17.
   PubMed Web of Science ®Google Scholar
• McIntosh MW, Drescher C, Karlan B, Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9–15.
   PubMed Web of Science ®Google Scholar
• Lambeck AJ, Crijns AP, Leffers N, Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: A potential role for interleukin 7. Clin Cancer Res 2007;13:2385–2391.
   PubMed Web of Science ®Google Scholar
• Chen YT, Scanlan MJ, Sahin U, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:1914–1918.
   PubMed Web of Science ®Google Scholar
• Nelson PT, Zhang PJ, Spagnoli GC, Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 2007;7:1.
   PubMedGoogle Scholar
• Valmori D, Qian F, Ayyoub M, Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 2006;12:398–404.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Gnjatic S, Sabbatini P, Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008;14:2740–2748.
   PubMedGoogle Scholar
• Li S, Meng L, Zhu C, The universal overexpression of a cancer testis antigen HIWI is associated with cancer angiogenesis. Oncol Rep 2010;23:1063–1068.
   Google Scholar
• Chen YT, Hsu M, Lee P, Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer 2009;124:2893–2898.
   PubMedGoogle Scholar
• Piura B, Piura E. Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol 2009;581939:17.
   Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875–7880.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Salati E, Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 2002;94:2447–2453.
   PubMed Web of Science ®Google Scholar
• Straughn JM Jr, Shaw DR, Guerrero A, Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004;108:805–811.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Yu Y, Mirandola L, Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One 2010 May 12;5(5):e10471.
   Google Scholar
• Andre FE, Booy R, Bock HL, Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 2008;86:140–146.
   PubMed Web of Science ®Google Scholar
• Chang MH, You SL, Chen CJ, Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. J Natl Cancer Inst 2009;101:1348–1355.
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avila M, Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 2007;369:1693–1702.
   PubMed Web of Science ®Google Scholar
• Thun MJ, DeLancey JO, Center MM, The global burden of cancer: Priorities for prevention. Carcinogenesis 2010;31:100–110.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–1647.
   PubMed Web of Science ®Google Scholar
• Koos D, Josephs SF, Alexandrescu DT, Tumor vaccines in 2010: Need for integration. Cell Immunol 2010;263:138–147.
   Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245–252.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol. 2000;68:793–806.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109–1118.
   PubMed Web of Science ®Google Scholar
• Santin AD, Hermonat PL, Ravaggi A, Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro. Immunobiology 1999;200:187–204.
   PubMed Web of Science ®Google Scholar
• Santin AD, Hermonat PL, Ravaggi A, In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601–609.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 2001;30:33–45.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Liu Y, Salati E, Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 2002;32:30–38.
   PubMed Web of Science ®Google Scholar
• Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010;2:37–56.
   PubMed Web of Science ®Google Scholar
• Yu Y, Pilgrim P, Zhou W, rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol 2008;21:435–442.
   Google Scholar
• Palladino G, Scherle PA, Gerhard W. Activity of CD4+ T-cell clones of type 1 and type 2 in generation of influenza virus-specific cytotoxic responses in vitro. J Virol 1991;65:6071–6076.
   PubMedGoogle Scholar
• Nonacs R, Humborg C, Tam JP, Steinman RM. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J Exp Med 1992;176:519–529.
   Google Scholar
• Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: Properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984;51:611–619.
   Google Scholar
• Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998;72:5919–5926.
   PubMed Web of Science ®Google Scholar
• Fisher-Adams G, Wong KK Jr, Podsakoff G, Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996;88:492–504.
   Google Scholar
• Chiriva-Internati M, Liu Y, Weidanz JA, Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 2003;102:3100–3107.
   PubMed Web of Science ®Google Scholar
• Bohenzky RA, LeFebvre RB, Berns KI. Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat. Virology 1988;166:316–327.
   Google Scholar
• Duan D, Sharma P, Yang J, Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8568–8577.
   PubMed Web of Science ®Google Scholar
• Monahan PE, Samulski RJ, Tazelaar J, Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998;5:40–49.
   PubMed Web of Science ®Google Scholar
• Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997;8:659–669.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Maxfield DG, Goodman SM, Feschotte C. Parallel germline infiltration of a lentivirus in two Malagasy lemurs. PLoS Genet 2009;5:20.
   Google Scholar
• Sabatino DE, Mingozzi F, Hui DJ, Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 2005;12:1023–1033.
   PubMed Web of Science ®Google Scholar
• Curielj TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–949.
   Google Scholar
• Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538–18543.
   PubMed Web of Science ®Google Scholar
• Giuntoli RL 2nd, Webb TJ, Zoso A, Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Res 2009;29:2875–2884.
   Google Scholar
• Gray A, de la Luz Garcia-Hernandez M, van West M, Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2009;30:G52–G59.
   Google Scholar
• Warrino DE, Olson WC, Scarrow MI, Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol 2005;66:762–772.
   Google Scholar
• Kriegel MA, Li MO, Sanjabi S, Transforming growth factor-beta: Recent advances on its role in immune tolerance. Curr Rheumatol Rep 2006;8:138–144.
   PubMedGoogle Scholar
• Rosano L, Varmi M, Salani D, Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001;61:8340–8346.
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Haisley C, Hurteau J, Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001;80:245–253.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zou L, Rodriguez P, B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871–881.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Vatan L, Cutting edge: Opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 2007;179:1423–1426.
   Google Scholar
• Wei S, Kryczek I, Zou L, Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020–5026.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, T cell apoptosis by kynurenines. Adv Exp Med Biol 2003;527:183–190.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147–1154.
   PubMed Web of Science ®Google Scholar
• Copier J, Dalgleish AG, Britten CM, Improving the efficacy of cancer immunotherapy. Eur J Cancer 2009;45:1424–1431.
   PubMed Web of Science ®Google Scholar
• Reali E, Canter D, Zeytin H, Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 2005;23:2909–2921.
   PubMed Web of Science ®Google Scholar
• Limpens J, Scheper RJ. Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site. Clin Exp Immunol 1991;84:383–388.
   Google Scholar
• Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine. Biologics 2007;1:173–181.
   Google Scholar
• Karbach J, Gnjatic S, Bender A, Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. Int J Cancer 2010;126:909–918.
   PubMed Web of Science ®Google Scholar
• Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9:28–38.
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U, Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 2007;178:2721–2729.
   Google Scholar
• Galli G, Pittoni P, Tonti E, Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 2007;104:3984–3989.
   PubMed Web of Science ®Google Scholar
• Choi YS, Hoory T, Monie A, alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 2008;26:5855–5863.
   Google Scholar
• Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1–12.
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr, Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403–415.
   PubMed Web of Science ®Google Scholar
• Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989;49:1649–1654.
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623–3633.
   PubMed Web of Science ®Google Scholar
• Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: Is it an immune suppressor? Cancer J 2010;16:354–359.
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165–5171.
   PubMed Web of Science ®Google Scholar
• Downs LS Jr, Judson PL, Argenta PA, A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112:331–339.
   Google Scholar
• Hurteau JA, Brady MF, Darcy KM, Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 2010;119:444–450.
   PubMed Web of Science ®Google Scholar
• Brabec V, Kasparkova J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Update 2005;8:131–146.
   PubMed Web of Science ®Google Scholar
• Lin YG, Immaneni A, Merritt WM, Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008;14:5437–5446.
   PubMed Web of Science ®Google Scholar
• Sawada K, Radjabi AR, Shinomiya N, c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670–1679.
   PubMed Web of Science ®Google Scholar
• Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85–94.
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360–4368.
   PubMed Web of Science ®Google Scholar
• Barre B, Vigneron A, Perkins N, The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4–11.
   Google Scholar
• Greenhill CJ, Rose-John S, Lissilaa R, IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2010;10:10.
   Google Scholar
• Duan Z, Bradner J, Greenberg E, 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 2007;72:1137–1145.
   PubMedGoogle Scholar
• Jarnicki AG, Conroy H, Brereton C, Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797–3806.
   PubMed Web of Science ®Google Scholar
• Adler HS, Kubsch S, Graulich E, Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood 2007;109:4351–4359.
   PubMed Web of Science ®Google Scholar
• Barber A, Zhang T, DeMars LR, Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67:5003–5008.
   PubMed Web of Science ®Google Scholar
• Bondurant KL, Crew MD, Santin AD, Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res 2005;11:3446–3454.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, O'Brien TJ, Underwood LJ, Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther 2002;2:97–105.
   PubMedGoogle Scholar
• Navabi H, Jasani B, Reece A, A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009;27:107–115.
   PubMed Web of Science ®Google Scholar
• Hernando JJ, Park TW, Fischer HP, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007;8:451–454, 2007.
   PubMed Web of Science ®Google Scholar
• Jin P, Han TH, Ren J, Molecular signatures of maturing dendritic cells: Implications for testing the quality of dendritic cell therapies. J Transl Med 2010;8:4.
   Google Scholar
• Roby KF, Niu F, Rajewski RA, Syngeneic mouse model of epithelial ovarian cancer: Effects of nanoparticulate paclitaxel, Nanotax. Adv Exp Med Biol 2008;622:169–181.
   PubMed Web of Science ®Google Scholar
• Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 2007;121:467–473.
   PubMed Web of Science ®Google Scholar
• Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010;363:479–481.
   PubMed Web of Science ®Google Scholar